Pharmafile Logo

Glaucoma in perspective

20 questions: Round 4

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve...

Inizio

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Inizio

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Inizio

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Inizio

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog...

Inizio

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

Inizio

- PMLiVE

Find your match in digital pharma marketing

Our Digital Lead, Richard Springham, looks at how to apply matchmaking lessons from Tinder to your own digital marketing.

Four Agency Worldwide

- PMLiVE

Chiesi Group’s Trimbow wins European licence

European Commission approves the COPD treatment

- PMLiVE

Two new starters boost Wave’s senior team

Sadaf Kazi and Dr Florentia Loizou join the group

- PMLiVE

Medmeme bolsters sales team

Appoints Jeff Sager as senior vice president

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

- PMLiVE

Xtandi slowdown weighs on Pfizer, but CEO won’t move on M&A

Investors call on the pharma giant to consider a large merger or acquisition deal

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links